Immune Thrombocytopenia (ITP) Clinical Trial
Official title:
A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
Primary Objective: - To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: - To assess the safety and tolerability of BIVV020 - To assess the pharmacokinetics of BIVV020 - To assess the response rate of treatment with BIVV020 - To assess the time to response - To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy - To assess the immunogenicity of BIVV020
Study duration: - Screening period: up to 56 days - Transition period between last sutimlimab dose and first dose of BIVV020 (for participants who were previously receiving sutimlimab): 14 days, included as part of the 56-day Screening period. Treatment duration: Minimum 52 weeks. Visit frequency: - Day 1 - Day 4 - Weeks 1 to 6: Weekly - Weeks 7 to 12: Every other week - Weeks 13 to 24: Every 4 weeks - Weeks 25+: At least every 8 weeks - End of Study visit: 22 weeks after the last dose of BIVV020 ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02868060 -
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
|
Phase 1/Phase 2 | |
| Completed |
NCT04346654 -
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
|
Phase 2 | |
| Not yet recruiting |
NCT06371417 -
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
|
Phase 1 | |
| Terminated |
NCT01054443 -
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
|
Phase 2 | |
| Recruiting |
NCT04915482 -
TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
|
Phase 2/Phase 3 | |
| Completed |
NCT00344149 -
Rituximab as Second Line Treatment for ITP
|
Phase 3 | |
| Completed |
NCT01666795 -
Autoantibody Specificity and Response to IVIG in ITP
|
N/A | |
| Terminated |
NCT05086744 -
Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
|
Phase 2 | |
| Recruiting |
NCT03951623 -
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
|
Phase 1 | |
| Recruiting |
NCT04968899 -
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
|
Phase 3 | |
| Recruiting |
NCT03975361 -
Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)
|
N/A |